tiprankstipranks
Advertisement
Advertisement

ACAD Stock Latest News

Acadia Announces Planned Retirement of Head of R&D
Company AnnouncementsAcadia Announces Planned Retirement of Head of R&D
7h ago
8K
ACAD
Acadia Pharmaceuticals price target lowered to $29 from $30 at RBC Capital
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $29 from $30 at RBC Capital
24d ago
ACAD
Acadia Pharmaceuticals announces Daybue Stix available in U.S.
PremiumThe Fly
Acadia Pharmaceuticals announces Daybue Stix available in U.S.
24d ago
ACAD
Arm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Arm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
1M ago
GM
ARE
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
PremiumThe Fly
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
1M ago
ACAD
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofA
PremiumThe FlyAcadia Pharmaceuticals upgraded to Buy from Neutral at BofA
1M ago
ACAD
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
Premium
Company Announcements
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
2M ago
8K
ACAD
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
Premium
The Fly
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
2M ago
ACAD
Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
2M ago
ACAD
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
PremiumRatings
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
2M ago
ACAD
ACADIA Pharmaceuticals Charts Growth Path After Record Year
PremiumCompany Announcements
ACADIA Pharmaceuticals Charts Growth Path After Record Year
2M ago
ACAD
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
2M ago
ACAD
Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
PremiumThe FlyAcadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
2M ago
ACAD
Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
Premium
The Fly
Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
2M ago
ACAD
Acadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
Premium
The Fly
Acadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
2M ago
ACAD
Acadia Pharmaceuticals price target raised to $35 from $34 at Citizens
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $35 from $34 at Citizens
2M ago
ACAD
Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA
PremiumRatings
Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA
2M ago
ACAD
ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
PremiumRatings
ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
2M ago
ACAD
Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia
PremiumRatings
Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia
2M ago
ACAD
Acadia Pharmaceuticals reports Q4 EPS $1.60 vs 86c last year
PremiumThe FlyAcadia Pharmaceuticals reports Q4 EPS $1.60 vs 86c last year
2M ago
ACAD
Acadia Pharmaceuticals sees FY26 revenue $1.22B-$1.28B, consensus $1.2B
Premium
The Fly
Acadia Pharmaceuticals sees FY26 revenue $1.22B-$1.28B, consensus $1.2B
2M ago
ACAD
Acadia Pharmaceuticals initiated with an Outperform at Wolfe Research
Premium
The Fly
Acadia Pharmaceuticals initiated with an Outperform at Wolfe Research
2M ago
ACAD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >